Ongoing Trial of Abemaciclib and Pembrolizumab in HR+/HER2-Negative Breast Cancer

During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

A regimen using the PD-L1 inhibitor atezolizumab in the neoadjuvant and adjuvant settings did not improve outcomes in patients with triple-negative breast cancer.

Matthew Hadfield, DO, discusses his passion for early-stage clinical trials and the need for more research into immunotherapy toxicities during the third episode of Emerging Experts.

A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.

An analysis of phase 3 trials found tamoxifen significantly reduced 15-year ipsilateral breast recurrence in patients with “good risk” DCIS treated without radiation therapy.